CTIS2023-507075-22-00
Recruiting
Phase 1
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients
Eurofins Optimed0 sites120 target enrollmentSeptember 1, 2023
ConditionsA Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s diseaseTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease
- Sponsor
- Eurofins Optimed
- Enrollment
- 120
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Study to evaluate the effects of new drug of diabetes mellitus in healthy volunteers.CTRI/2016/01/006507Cadila Pharmaceuticals Ltd36
Active, not recruiting
Phase 1
A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Months old, InclusivePediatric subjects with GERDMedDRA version: 9.1Level: LLTClassification code 10018203Term: GERDEUCTR2008-000452-27-BEJanssen-Cilag International N.V.49
Active, not recruiting
Phase 1
Study of Rabeprazole in Pediatric Subjects aged 1 to 11 months with acid reflux diseasePediatric subjects with GERDMedDRA version: 13.1 Level: LLT Classification code 10018203 Term: GERD System Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]EUCTR2008-000452-27-GBJanssen-Cilag International N.V.49
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AEUCTR2016-002396-99-FRovo Nordisk A/S36
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AHaemophilia AMedDRA version: 19.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2016-002396-99-DEovo Nordisk A/S48